Monitor FDA review progress and any updates on modular review acceptance. The RMAT designation allows for rolling and priority review, which could accelerate timeline. Approval would open a new market in LVAD-related complications, but clinical data adequacy remains key.
Drug in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this 6-K- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $14.09entry
- T+1 · 5mo ago +2.06%α +2.19% · $14.38
- T+5 · 4mo ago +1.42%α +1.16% · $14.29
- T+20 · 4mo ago +0.28%α +2.47% · $14.13
- T+60 · 8w ago +9.87%α +6.99% · $15.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast received a BLA filing number from the FDA and requested a modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. The drug has Orphan Drug and RMAT designations, and the company highlighted recent FDA guidance on regulatory flexibility for orphan rare diseases. This is a positive regulatory milestone but does not guarantee approval.
Key Facts
- Received BLA filing number from FDA for rexlemestrocel-L in end-stage heart failure with LVADs
- Requested modular review of the BLA
- Rexlemestrocel-L has Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations
- FDA recently issued draft guidance on flexibility for demonstrating substantial evidence of effectiveness for orphan rare diseases
Financial Impact
No financial figures disclosed; regulatory milestone with potential future revenue if approved
Risk Factors
- FDA may not accept modular review or may require additional clinical data
- Competition from other therapies for LVAD-related gastrointestinal bleeding
- Commercial adoption depends on pricing and reimbursement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000062 |
| Exhibit: exhibit991lvadblasubmiss.htm | 0001345099-26-000062 |
| Document: 0001345099-26-000062-index-headers.html | 0001345099-26-000062 |
| Document: 0001345099-26-000062-index.html | 0001345099-26-000062 |
| Document: 0001345099-26-000062.txt | 0001345099-26-000062 |
Track record
25 reports on MESO
6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers